Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc reported that alixorexton, its investigational orexin 2 receptor agonist for sleep disorders, has received orphan drug designations in both the U.S. and Europe. The FDA granted orphan status for idiopathic hypersomnia, while the European Commission granted orphan status for narcolepsy.
Alixorexton is in phase 3 Brilliance studies for narcolepsy types 1 and 2 and in the phase 2 Vibrance-3 study for idiopathic hypersomnia. Orphan designation can provide tax credits, reduced regulatory fees and market exclusivity, supporting development of this potential treatment for rare, chronic neurological conditions.
Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at a price of $45.10 per share. After this transaction, he directly holds 25,680 Ordinary Shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Wright on March 11, 2026, indicating the trade was scheduled in advance rather than timed discretionarily.
Alkermes plc submitted a Rule 144 notice related to 2,000 shares of Common Stock tied to the vesting of restricted stock unit awards on 05/21/2026. The filing lists a shares outstanding figure of 166,675,807 as of 06/12/2026 as context.
Alkermes plc EVP and Chief Legal Officer David Joseph Gaffin reported an open-market sale of 2,034 Ordinary Shares of Alkermes on June 4, 2026 at an average price of $43.05 per share. After this transaction, he directly holds 229,524 Ordinary Shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that he adopted on November 19, 2025, indicating it was scheduled in advance rather than timed opportunistically.
Alkermes plc submitted a Form 144 notice concerning proposed sales of Common Stock on 06/04/2026 for shares traded on NASDAQ. The filing lists vested restricted stock unit awards of 506 (03/03/2015) and 1,528 (03/01/2018) shares and records four prior sales in the past three months: 59,575.86, 60,531.84, 70,315.38, and 67,528.80.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 5,000 Ordinary Shares at $19.34 per share and sold 9,000 Ordinary Shares in an open-market transaction at a weighted average price of $41.6715 per share.
Both the option exercise and the share sale were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025, meaning they were pre-arranged. The sale price reflects multiple trades between $41.37 and $42.19. After these transactions, Hopkinson directly holds 77,389 Ordinary Shares.
Craig Hopkinson reported dispositions of Alkermes plc ordinary shares via Form 144. The filing lists three sales of 9,000 shares each on 03/02/2026, 04/01/2026, and 05/01/2026, with proceeds shown as $267,485.14, $319,604.00, and $300,559.55 respectively. The record also shows recent issuer-related activity including a broker-assisted cashless exercise of 5,000 shares on 06/01/2026 and a vesting of a performance share award of 4,000 shares on 02/05/2026.
Alkermes plc VP of Finance (Interim PAO) Samuel Joseph Parisi reported an exercise-and-sell transaction in company stock. On May 29, 2026, he exercised employee stock options to acquire a total of 16,217 Ordinary Shares at exercise prices of $19.34 and $20.03 per share. He then sold 16,217 Ordinary Shares in open-market transactions at a weighted average price of $42.3634 per share, with individual sale prices ranging from $42.245 to $42.50. After these transactions, he directly held 7,717 Ordinary Shares of Alkermes.
Alkermes plc director Christopher I. Wright reported several compensation-related equity transactions. On May 21, 2026, 6,142 restricted stock units were exercised into ordinary shares, with 1,475 shares withheld at $36.95 per share to cover tax obligations rather than sold on the market. Wright also received new awards on May 20, 2026: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price, expiring on May 20, 2036. Following these transactions, he holds 27,680 ordinary shares directly. Footnotes clarify each restricted stock unit converts into one ordinary share and that the new awards vest in full around the next annual general meeting.
Alkermes plc. director Wilson Frank Anders reported several routine equity compensation moves. On May 21, 2026, he exercised 6,142 Restricted Stock Units, receiving the same number of ordinary shares, and had 1,475 ordinary shares withheld to cover tax obligations at $36.95 per share. Following these transactions, he directly held 37,226 ordinary shares.
On May 20, 2026, he received a new grant of 5,409 Restricted Stock Units, each representing a contingent right to one ordinary share, and a Non Qualified Stock Option for 11,538 ordinary shares with an exercise price of $36.98 per share, expiring on May 20, 2036. The filing describes these events as grants, vesting, and tax-withholding rather than open-market buying or selling.